PMID- 34488400
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20210908
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 8
DP  - 2021 Aug
TI  - Vascular normalization therapy with targeted localized vessel bevacizumab 
      infusion in hepatocellular carcinoma after transarterial chemoembolization 
      failure.
PG  - 9149-9156
LID - 10.21037/apm-21-2123 [doi]
AB  - BACKGROUND: Hepatocellular carcinoma (HCC) is a highly vascularized tumor in 
      which abnormal blood vessels contribute to poor treatment efficacy and prognosis. 
      In this study, we assessed the efficacy, safety, and potential ability of 
      bevacizumab to normalize tumor vascularity in patients with advanced HCC. 
      METHODS: Patients with histologically or clinically confirmed advanced HCC that 
      were refractory to conventional transarterial chemoembolization (c-TACE) received 
      a transarterial infusion of bevacizumab (5 mg/kg), followed by c-TACE (named as 
      BEVA-TACE). The primary endpoint was overall survival (OS), which was defined as 
      the time from a patient identified as TACE refractory to the occurrence of death. 
      The secondary endpoints included progression-free survival (PFS) and the disease 
      control rate (DCR). RESULTS: From January 2014 to December 2017, 20 patients with 
      Barcelona Clinic Liver Cancer (BCLC) staging scores C (80.0%) or D (20.0%) 
      received BEVA-TACE. The median OS time was 9.2 months [95% confidence interval 
      (CI): 2.1-22.6 months]. The median PFS time was 6.3 months (95% CI: 1.0-10.5 
      months). Despite the late stage, 1 patient (5.0%) had a complete response (CR), 6 
      patients (30.0%) had a partial response (PR), and 10 patients (50.0%) had stable 
      disease (SD) [overall response rate (ORR) 30.0%; DCR 85.0%]. The most common 
      adverse events (AEs) were postembolic syndrome (25%), hyperbilirubinemia (10.0%), 
      and melena (10.0%). Severe III-IV oral mucositis and hypertension were observed 
      in only 1 patient (5.0%) during the follow-up period. CONCLUSIONS: BEVA-TACE 
      showed clinical efficacy, and patients with TACE-refractory HCC had acceptable AE 
      rates. A low dose of targeted localized vessel bevacizumab infusion may normalize 
      the condition of tumor blood vessels in patients with advanced HCC.
FAU - Zhang, Haixiao
AU  - Zhang H
AD  - Interventional Radiology Department, The First Affiliated Hospital of Xinjiang 
      Medical University, Wulumuqi, China.
FAU - Cao, Gengfei
AU  - Cao G
AD  - Interventional Radiology Department, The First Affiliated Hospital of Xinjiang 
      Medical University, Wulumuqi, China.
FAU - Ren, Weixin
AU  - Ren W
AD  - Interventional Radiology Department, The First Affiliated Hospital of Xinjiang 
      Medical University, Wulumuqi, China.
FAU - Gu, Junpeng
AU  - Gu J
AD  - Interventional Radiology Department, The First Affiliated Hospital of Xinjiang 
      Medical University, Wulumuqi, China.
FAU - Ji, Weizheng
AU  - Ji W
AD  - Interventional Radiology Department, The First Affiliated Hospital of Xinjiang 
      Medical University, Wulumuqi, China.
FAU - Zhu, Diwen
AU  - Zhu D
AD  - Interventional Radiology Department, The First Affiliated Hospital of Xinjiang 
      Medical University, Wulumuqi, China.
FAU - Bao, Yingjun
AU  - Bao Y
AD  - Interventional Radiology Department, The First Affiliated Hospital of Xinjiang 
      Medical University, Wulumuqi, China.
FAU - Hasimu, Asihaer
AU  - Hasimu A
AD  - Interventional Radiology Department, The First Affiliated Hospital of Xinjiang 
      Medical University, Wulumuqi, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Bevacizumab/therapeutic use
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - *Chemoembolization, Therapeutic
MH  - Combined Modality Therapy
MH  - Humans
MH  - *Liver Neoplasms/drug therapy
OTO - NOTNLM
OT  - Hepatocellular carcinoma (HCC)
OT  - bevacizumab
OT  - vascular normalization therapy
EDAT- 2021/09/08 06:00
MHDA- 2021/09/09 06:00
CRDT- 2021/09/07 05:44
PHST- 2021/07/07 00:00 [received]
PHST- 2021/08/19 00:00 [accepted]
PHST- 2021/09/07 05:44 [entrez]
PHST- 2021/09/08 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
AID - 10.21037/apm-21-2123 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Aug;10(8):9149-9156. doi: 10.21037/apm-21-2123.